An observational study in COVID-19, ARDS, Human and Cardiac Failure, sponsored by Region Stockholm. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-09.
Sponsored by Region Stockholm · Observational
We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", in which we analysed the echocardiographic data collected both at baseline when patients where included and 3-5 days later for followup.
We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure" which was conducted in 2020/2021 during the COVID-19 pandemic on patients with ARDS due to COVID and requiring mechanical ventialtion. Patients underwent echocardiography at baseline, and were then randomized either to control, or treatment with inhaled nitric oxide, starting at 80ppm and then 40ppm. Followup echocardiography was performed 3-5 days later, and all echocardiographies were conducted by highly experienced sonographeres certified by the European Association of Cardiovascular Imaging. Analysis of these cardiac ultrasounds focused on the amount of patients showing signs of pulmonary hypertension, right ventricular failure and left ventricular failure. Several parameters were used to estimate these, and we also aimed to evalute the utility of more novel measures such as RV and LV GLS for this use in the ICU.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 39 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →Region Stockholm is the lead sponsor of 121 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A population studied in the trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", consisting of 40 patients recruited in the ICU at Danderyds Hospital at the height of the COVID-19 pandemic. The study population consisted of critically ill patients requiring mechanical ventilation suffering from verified COVID-19 with ARDS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Delta MPAP
Difference in MPAP, measured at baseline and at followup
Time frame: 3-5 days
Delta RV GLS
Difference in RV GLS, measured at baseline and at followup
Time frame: 3-5 days
Delta TAPSE
Difference in TAPSE, measured at baseline and at followup
Time frame: 3-5 days
Delta EF
Difference in EF, measured at baseline and at followup
Time frame: 3-5 days
Delta CI
Difference in CI, measured at baseline and at followup
Time frame: 3-5 days
Delta LV GLS
Difference in LV GLS, measured at baseline and at followup
Time frame: 3-5 days
Rates of LV failure detected by LV GLS compared to EF
Comparison of the amount of patients with LV failure for LV GLS and for EF, presented at both timepoints
Time frame: Presented both at baseline and followup
Rates of RV failure detected by RV GLS compared to TAPSE
Comparison of the amount of patients with RV failure for RV GLS and for TAPSE, presented at both timepoints
Time frame: Presented both at baseline and followup
Associations between levels of pulmonary hypertension, PEEP, peak pressures, central venous pressures and measurements
Regression analysis will be performed to check for association between these potential confounders
Time frame: 3-5 days
Associations between levels of pulmonary hypertension, PEEP, peak pressures, central venous pressures and measurements
Regression analysis will be performed to check for association between these potential confounders and RV function, to be corrected for if applicable
Time frame: Baseline and followup 3-5 days later
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2020 to primary completion in Feb 2021, 9 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 9 months is below that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.